Gene · 9113
Papers3,081
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 3,081
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Engineered nanovesicle platform simultaneously triggers YAP-dependent ferroptosis and reprograms T-cell immunity through miR-150-3p codelivery in melanoma microenvironment. | Theranostics | 2025 | 40860143 | PubTator, text mining | PubMed |
| Fenofibrate-mediated inhibition of tumor proliferation and progression by modulating the PTPN14/MARK3/Hippo signaling axis. | Pharmacol Res | 2025 | 40858196 | PubTator, text mining | PubMed |
| Biomolecular phase separation in tumorigenesis: from aberrant condensates to therapeutic vulnerabilities. | Mol Cancer | 2025 | 40849651 | PubTator, text mining | PubMed |
| HOMER3 orchestrates SRC-YAP1 activity that promotes tumor cell growth and antagonizes anti-tumor immunotherapy in prostate cancer. | Oncogene | 2025 | 40849586 | PubTator, text mining | PubMed |
| The components and regulation of the Hippo pathway and its relationships with the progression and treatment of Non-small cell lung cancer (NSCLC). | Cancer Cell Int | 2025 | 40830878 | PubTator, text mining | PubMed |
| Lactylation-mediated miRNA regulation in cancer therapy resistance. | J Transl Med | 2025 | 40830798 | PubTator, text mining | PubMed |
| Protein modifications by advanced glycation end products (AGEs) in human clear cell renal cell carcinoma. | J Transl Med | 2025 | 40813989 | PubTator, text mining | PubMed |
| The Effects of Rukangyin on the Biological Behavior and Hippo Signaling Pathway in MDA-MB-231 Breast Cancer Cells. | Curr Pharm Biotechnol | 2025 | 40776641 | PubTator, text mining | PubMed |
| Discovery and Optimization of LATS1 and LATS2 Kinase Inhibitors for Use in Regenerative Medicine. | J Med Chem | 2025 | 40768682 | PubTator, text mining | PubMed |
| RNA Epigenetics in Cancer: Current Knowledge and Therapeutic Implications. | MedComm (2020) | 2025 | 40761481 | PubTator, text mining | PubMed |
| Histomorphological and molecular characteristics of liposarcoma (Review). | Oncol Lett | 2025 | 40747377 | PubTator, text mining | PubMed |
| Pipeline to evaluate YAP-TEAD inhibitors indicates TEAD inhibition represses NF2-mutant mesothelioma. | Life Sci Alliance | 2025 | 40744733 | PubTator, text mining | PubMed |
| Peptide Drug: Design and Clinical Applications. | MedComm (2020) | 2025 | 40717901 | PubTator, text mining | PubMed |
| YTHDF2 alleviates the radioresistance of rectal cancer cells by targeting methylated MYC. | J Radiat Res | 2025 | 40716096 | PubTator, text mining | PubMed |
| Liquid-liquid phase separation of GPS2-LATS1 promotes colorectal cancer progression by reprogramming lipid metabolism. | Oncogene | 2025 | 40715488 | PubTator, text mining | PubMed |
| Investigating LATS1 and NF-κB as Predictors of Radiotherapy Response in Cervical Cancer. | Curr Issues Mol Biol | 2025 | 40699764 | PubTator, text mining | PubMed |
| Stiffness sensing fuels matrix-driven metabolic reboot for kidney repair and regeneration. | bioRxiv | 2025 | 40667238 | PubTator, text mining | PubMed |
| Hippo Pathway Dysregulation in Thymic Epithelial Tumors (TETs): Associations with Clinicopathological Features and Patients' Prognosis. | Int J Mol Sci | 2025 | 40649713 | PubTator, text mining | PubMed |
| Discovery of 2-Pyrazolylpyrimidinone Derivatives as New SPOP Inhibitors for Renal Cell Carcinoma Therapy. | J Med Chem | 2025 | 40622869 | PubTator, text mining | PubMed |
| The interplay between oxytocin receptor and YAP in regulating gastric cancer progression. | Oncogene | 2025 | 40604321 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9113/papers?page=6